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Background: Sleep disturbances (SD) are the most impactful and commonly reported
symptoms in post-traumatic stress disorder (PTSD). Yet, they are often resistant to primary
PTSD therapies. Research has identified two distinct SDs highly prevalent in PTSD; insom-
nia and nightmares. Those who report SDs prior to a traumatic event are at greater risk for
developing PTSD; highlighting that sleep potentially plays a role in PTSD’s pathology. To
further understand the pathobiological mechanisms that lead to the development of PTSD, it
is first imperative to understand the interplay which exists between sleep and PTSD on a
biological level. The aim of this systematic review is to determine if biological or physio-
logical markers are related to SD in PTSD.
Methods: A systematic literature search was conducted on the electronic databases;
Medline, Embase, AMED and PsycINFO, using Medical Subject Headings and associated
keywords.
Results: Sixteen studies were included in the final analyses. Physiological makers of
autonomic function, and biochemical markers of HPA-axis activity; inflammatory processes;
and trophic factor regulation were related to the severity of SDs in PTSD.
Conclusion: These findings add to the growing literature base supporting a central focus on
sleep in research aiming to define the pathophysiological processes which result in PTSD, as
well as emphasising the importance of specifically targeting sleep as part of a successful
PTSD intervention strategy. Resolving SDs will not only reduce PTSD symptom severity and
improve quality of life but will also reduce all-cause mortality, hospital admissions and
lifetime healthcare costs for those with PTSD. Limitations of the current literature are
discussed, and key recommendations future research must adhere to are made within.
Keywords: post-traumatic stress disorder, sleep disturbances, insomnia, nightmares,
biomarkers
Introduction
Post-traumatic stress disorder (PTSD) is a debilitating condition which may
develop following exposure to, witnessing, or learning about, a traumatic event
such as; actual or threatened death, actual or threatened serious injury, or actual or
threatened sexual violence.1 These events are referred to as criterion A events, as
per the diagnostic and statistical manual of mental disorders, fifth edition
(DSM-5).1
A diagnosis of PTSD is made based on the presentation of symptoms, which are
arranged into four symptom clusters; alterations in arousal and reactivity, intrusions,
Correspondence: Mark W Ruddock
Tel +44 02894422413
Email Mark.Ruddock@randox.com
Nature and Science of Sleep Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Nature and Science of Sleep 2020:12 545–562 545
http://doi.org/10.2147/NSS.S260734
DovePress © 2020 Maguire et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
avoidance and negative alterations in cognitions and
mood.1 Lifetime prevalence of PTSD is approximately
2–8%, but this differs by geographical location and the
level of trauma exposure experienced in a particular
population.2–5 As an example, military and emergency
service personnel are exposed to more trauma than the
general population, which is reflected in their respective
PTSD prevalence rates of 13.4% and 22%.3,4,6-9
Sleep Disturbances as a Core Pathological
Factor in PTSD
Difficulty sleeping is considered one of the most commonly
experienced symptoms of PTSD,5,10,11 Two distinct sleep
disruptions exist, insomnia (persistent difficulty falling
asleep or staying asleep) and nightmares. These fall under
the DSM−5 PTSD symptom clusters of “alterations in arou-
sal and reactivity” and ‘intrusions’, respectively.1 A recent
survey of 2,647 US adults exposed to potentially traumatic
events by Milanak et al (2019) found that 92% of those who
met the criteria for PTSD experienced at least one symptom
of disturbed sleep.10 Although experiencing insomnia and
nightmares together accounted for the majority of SDs in
PTSD, Milanak et al (2019) noted that where only a single
sleep disturbance was endorsed, insomnia was more preva-
lent than nightmares (56.7% vs 24.9% vs 11.3%).10
Avariation in the prevalence of SDs in PTSD is common
in the literature.12–14 Some of this variability may be
explained by differences in population demographics such
as sex and level and type of trauma exposure. However, the
effect these, and other population factors have on the endor-
sement of SDs in PTSD, requires further research.
Methodological differences in measuring sleep is a further
source of variability. Modern sleep research has capitalized
on advancements in wearable technology to provide objec-
tive measures of sleep in the free-living environment.15–18
Actigraphy is the most common method, and involves parti-
cipants wearing a personal accelerometer device, normally
on the wrist, to record movement during sleep.19–21 This
movement data is then translated to provide information
about a participants’ sleep.22–24 Incorporation of objective
methods, such as actigraphy, improves upon a sole reliance
on subjectively reported sleep.17
Sleep is a central treatment and research objective in
PTSD, and may represent a modality through which PTSD
treatment uptake can be improved, due to a lack of the
stigmatization associated with other PTSD symptomology.11
However, the paradigm of causality between PTSD and
disrupted sleep (both nightmares and insomnia) remains
ambiguous. Originally considered merely as symptoms of
PTSD, recent studies have established a theory of sleep
disturbances preceding traumatic exposure as a risk factor
for PTSD development.25,26 Longitudinal examination of a
Dutch military cohort by Van Liempt et al (2013) revealed
that experiencing nightmares before combat deployment, was
somewhat predictive of the development of PTSD post-
deployment.27 Furthermore, experiencing insomnia immedi-
ately following trauma exposure has been found to be pre-
dictive of PTSD development a year later, suggesting that a
potentially stunted ability of sleep to consolidate memory
could contribute to the development of PTSD.28 Moreover,
primary therapies specifically targeting PTSD, such as cog-
nitive behavioural therapy (CBT) for PTSD, are often insuf-
ficient to completely improve SDs despite a reduction in
other PTSD attributable symptoms.29 This would appear to
suggest that SDs, both insomnia and nightmares, are a com-
ponent of the pathology of PTSD, rather than solely a symp-
tom; a hypothesis also postulated for depression and anxiety
disorders.30–32
Improving sleep quality has been associated with a
clinically relevant reduction in the severity and impact of
PTSD symptomology, thus highlighting the importance of
specifically targeting sleep as part of a multi-faceted
approach for PTSD treatment.33–35 Despite these findings,
and high prevalence, a specific mechanistic role of sleep in
PTSD, as well as the reciprocal nature of the relationship
between SDs and PTSD, remains to be established.25
Furthermore, subjective and objective sleep measures
have yielded conflicting reports on the number of awaken-
ings and sleep duration in PTSD, depending on the com-
parative population used.12,14,36,37 Therefore, to fully
establish the directionality of the relationship between
PTSD and disordered sleep, and the individual contribu-
tions of insomnia and nightmares, there is a need to
examine if an interplay exists between these factors on a
biological level.
HPA-Axis Regulation and Inflammation in
PTSD
To determine any biological interconnection between sleep
and PTSD, it is important to first consider each separately.
The pathobiology of PTSD remains an active area of
research, which to date has focused mainly on two func-
tional systems; 1) the hypothalamic-pituitary-adrenal
(HPA) axis and 2) systemic inflammation.
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PTSD and the Hypothalamic-Pituitary-Adrenal Axis
(HPA-Axis)
Exposure to a threat, which may be either physical or
psychological, triggers a physiological response. Termed
the “stress response”, this results in the activation of
biological mechanisms which allow a reaction to the
threat. Central regulation of this process is facilitated by
the HPA-axis, functional alterations to which have been
linked to psychiatric conditions such as depression, anxi-
ety and PTSD.38,39
Following exposure to a stressor, neurons of the para-
ventricular nucleus (PVN) in the hypothalamus respond by
releasing corticotrophin-releasing hormone (CRH) and
arginine vasopressin (AVP) into hypophysial portal
blood, causing the pituitary gland to release adrenocorti-
cotrophic hormone (ACTH) into the general circulation.40
ATCH acts on the adrenal glands to stimulate the synthesis
and release of glucocorticoids, of which cortisol is the
primary in humans.40 Regulation of HPA-axis activity is
facilitated by cortisol-mediated negative feedback on the
anterior pituitary, PVN and hippocampus, resulting in an
inhibition of CRH, AVP and ACTH release.40
Two cortisol receptors exist in humans: mineralocor-
ticoid receptors, which function as high-affinity cortisol
stores, and functionally active glucocorticoid receptors
(GRs).40 FK506 binding protein (FKBP5) has recently
been characterised as a functional inhibitor of GRs, pre-
venting their activation by lowering the GRs affinity for
cortisol binding.41 Longitudinal examination of FKPB5
mRNA expression in a military cohort, revealed low pre-
deployment expression was predictive of PTSD occur-
rence post deployment, a finding replicated in further
studies.41–45 This would appear to suggest that a stunted
inhibition of the HPA-axis stress response could contri-
bute to the pathobiology of PTSD. However, further
research is required to explore this hypothesis as contra-
dictory findings, such as elevated and attenuated cortisol
levels, remain. Albeit, these may be somewhat explained
by differences in comparative control populations, gender
differences, types of traumatic events experienced and
sampling time and conditions.46 Despite controversy
over the exact functional response of the HPA-axis in
PTSD, inhibitors of FKPB51, the functional protein pro-
duced in response to FKBP5 expression, are being devel-
oped with the aim to use as novel therapies in the
treatment of psychiatric conditions such as PTSD and
depression.39 Further understanding of the HPA-axis,
GRs and associated molecular partners, in psychiatric
disorders, is required before any therapeutic potential of
such FKBP51 antagonists can be discussed. However, by
inhibiting the activity of FBKP51 without activating GRs
themselves, such antagonists may prove useful experi-
mental tools to aid in this endeavour.39
PTSD and Systemic Inflammation
PTSD has been hypothesised to be accompanied by a
systemic rise in pro-inflammatory activity.47 Activation
of cytotoxic T lymphocytes in response to stress (physical
or psychological), results in an inflammatory response
dominated by Th2 type cells, producing an unrestrained
production of pro-inflammatory cytokines.48,49 It is there-
fore unsurprising that in a recent meta-analysis of inflam-
matory markers in PTSD, increased pro-inflammatory
interleukin−6 (IL−6), IL−1β, TNF-α and interferon
gamma (INF-γ) were observed.50 This is supported by
increased inflammation present in the peripheral circula-
tion, adrenal glands and neurological tissue of predator
exposure mouse models of PTSD.51
Further fitting this inflammatory hypothesis is the
established increased incidence of cardiovascular disease,
type 2 diabetes, chronic fatigue syndrome and other
metabolic syndromes in PTSD populations, conditions
which are progressed by dysregulated inflammatory
processes.52–59 Pathological inflammation is also demon-
strated to result in neuronal loss, which is interesting
considering the loss of hippocampal volume noted in
both humans and mouse models of PTSD.60–62
PTSD and Trophic Factors
Trophic factors, such as Brain-Derived Neurotrophic Factor
(BDNF), Nerve Growth Factor (NGF) and Vascular
Endothelial Growth Factor (VEGF), are central regulators
of the CNS, essential for maintaining synaptic plasticity,
learning and memory.63–65 In the context of psychiatric
disorders, trophic factors have demonstrated altered expres-
sion levels in both PTSD and depression, although their
exact functional role remains ill-defined.66–68 The literature
surrounding trophic factors and PTSD remains particularly
unclear, with findings often opposing one and other.69–71
The intertwined relationship between trophic factors and
sleep is particularly interesting in this case. BDNF and its
molecular coplayers may have a central role in sleep home-
ostasis, particularly slow-wave sleep.72 Trophic factors may
therefore serve as a linchpin in the relationship between
PTSD and its related SDs.
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Interconnections Between Sleep and
PTSD Pathophysiology
The physiological role of sleep remains the focus of much
research but elucidated roles include cellular and tissue
repair, cognitive and memory processing, maintenance of
synaptic plasticity, through a process known as “pruning”,
and free radical detoxification.73,74 As such, disruption of
sleep through either sudden awakening from nightmares or
through reduction in consolidated, sustained sleep from
insomnia, may contribute to a host of pathophysiological
processes.
Pressure to fall asleep, facilitated by the circadian
drive, is enacted through melatonin secretion. Melatonin,
under the control of the suprachiasmatic nuclei (SCN), is
secreted from the pineal gland through metabolism of
serotonin, upon darkness onset.75 Light sensing is facili-
tated by direct communication of photoreceptive retinal
ganglion cells with the SCN via the retinohypothalamic
tract. Secretion increases at twilight, reaches a peak during
the middle of the night and then begins to decrease to
basal daytime levels.76 Metabolization of melatonin pri-
marily occurs in the hepatocytes of the liver where it
undergoes the process of hydroxylation, producing 6-
hydroxymelatonin which is then sulphated and excreted
in urine.77 However, the processes of demethylation, dea-
cetylation and oxidation also occur, albeit to a lesser
extent.78 Hypothesised to be resultant from a circadian
phase shift, alterations in melatonin production have been
noted in a range of neurological and neuropsychological
conditions however, this has not yet been noted in
PTSD.75,79
Therefore, it would be of interest to investigate the rate
and pathway of melatonin metabolization in PTSD, consid-
ering the neuroprotective-free radical scavenging properties
of melatonin oxidation products and the hypothesised
increased oxidative stress in PTSD.78 Moreover, the role of
melatonin in blood pressure regulation is interesting consid-
ering the persistently reported presence of hypertension diag-
noses in PTSD populations.80–83
Occurrence of metabolic and cardiovascular diseases
which result in increased mortality, similar to those
observed in PTSD populations, has been associated with
persistent insomnia in longitudinal analysis.84 Akin to that
previously mentioned in PTSD, elevation of inflammatory
status has been noted in populations with persistent insom-
nia, in the form of increased pro-inflammatory C-reactive
protein (CRP) and IL-6.85 It would therefore be of interest
to examine SDs of PTSD in relation to biological markers,
differentiating and examining the individual roles played
by insomnia and nightmares. SDs represent targetable
symptoms of PTSD that with successful treatment not
only have the potential to reduce PTSD symptomology
and improve quality of life but may also reduce lifetime
all-cause mortality among PTSD populations.
This review aims to systematically examine the litera-
ture to determine; 1) are biochemical or physiological
markers related to SDs in PTSD, 2) are biochemical or
physiological markers related to the degree of SD severity
in PTSD and, 3) does improvement in SDs result in a
change of biochemical or physiological markers in PTSD
populations?
Methodology
Following a broad review of the literature, a search strat-
egy was devised to identify research articles able to
address the question, “Are biological and physiological
markers related to sleep in PTSD?”. Set out in Table 1,
this strategy was used to search the electronic databases;
EMBASE, Medline, AMED and PsycINFO using the
Table 1 Literature Search Strategy, Consisting of Medical Subject
Headings (MeSH) and Keywords. OVID Online Platform Was to
Search EMBASE, Medline, AMED, PsychINFO Databases
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OVID online platform. Searches were carried out periodi-
cally between March 2018 and March 2020.
Inclusion Criteria
Studies were eligible for inclusion if they contained (1) a
human adult population, (2) a measurement of PTSD
(either valid self-assessment methods such as the PTSD
checklist (PCL), or clinical diagnosis), (3) a subjective or
objective measurement of sleep and (4) either a non-inva-
sive physiological measurement (independent of sleep
quantification method) or any biochemical assessment car-
ried out on a biological sample (blood/tissue). Randomized
control trials, cohort, case-controlled, and cross-sectional
studies were eligible for inclusion and were not limited
based on population gender, race, age or trauma exposure.
Included studies were limited to peer-reviewed articles
published in English between September 2008 and
March 2020.
Exclusion Criteria
Articles were excluded if they did not contain: (1) a PTSD
subpopulation or PTSD assessment, (2) a subjective or
objective measurement of sleep, and (3) a physiological
or biochemical measurement, independent of the sleep
quantification method. For example, for eligibility assess-
ment electroencephalogram (EEG), recorded as part of
polysomnography (PSG), was considered a component of
sleep measurement rather than a physiological measure-
ment. However, heart rate (HR) and peripheral oxygen
saturation were deemed appropriate as a physiological
measurement, if analysed independently of sleep.
Pharmacological treatment trials, either for sleep or
PTSD symptoms, were excluded. PTSD populations with
concurrent traumatic brain injury (TBI) were excluded to
minimise confounding of results. Case studies and confer-
ence abstracts were also excluded.
Screening and Data Extraction
The process of identifying, screening and assessing articles
for eligibility criteria is summarized in Figure 1. Using the
previously stated search strategy, 513 research entries were
identified, and their references imported to a web-based
reference management programme (RefWorks), for the
purpose of duplicate identification and removal. Removal
of duplicates resulted in 471 entries for title and abstract
screening. Article titles were screened for relevance to
PTSD and sleep, resulting in 129 being retained for
abstract review. Abstracts were examined to confirm a
PTSD population, a measure of sleep, a biological or
physiological measure and that the article was original
research. Where any details could not be established, arti-
cles were retained for full-text assessment. Following
abstract assessment, 38 articles were retained and subject
to full-text eligibility assessment. Sixteen articles were
deemed to meet the eligibility criteria and were included
in the final analyses.
Data extracted from the included articles (n=16)
encompassed; the authors, date of publication, study inclu-
sion and exclusion criteria, excluded participants, popula-
tion size, age, sex, study design, objective sleep
measurement, subjective sleep measurement, sleep inter-
vention, PTSD symptom assessment, physiological mea-
surement(s), biochemical measurement(s), gene expression
analysis, any additional measures, key findings and key
limitations. For each study, the results of this data extrac-
tion are set out in Table 2. Full references for each study
are available in the bibliography.
Quality Assessment
Criteria adapted from the Critical Appraisal Skills
Programme (CASP) checklist was used as a quality assess-
ment for each included article.86 Key findings of this
review were then subject to a quality of findings assess-
ment, using the Grading of recommendations, assessment,
development and evaluations (GRADE) criteria for sys-
tematic reviews.87 Results of GRADE analysis are shown
in Table 3, produced using GRADEpro Guideline
Development Tool [Software], McMaster University,
2015 (developed by Evidence Prime, Inc.), Available
from gradepro.org. Summary grades available are as fol-
lows; High (Confidence in the study findings is high);
Moderate (Confident that the effect observed is close to
the real effect but may also be substantially different);
Low (The true effect may differ significantly from that
observed); and Very Low (The effect is likely to be very
different from that observed).
Results
A total of 2,838 participants were included across the 16
studies, of which 68% were male and 30% female. No
information on sex was available for 2% of participants.
Most study populations were “male and female” (10/16),
three were “female only” and two “male only”. Sex was
not reported in the remaining study. The overall mean age
was 37.93 ± 7.35 years, with study mean ages ranging
from 21.7 to 51.4 years.
Dovepress Maguire et al
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Eight/16 studies consisted exclusive of military popu-
lations (active service and veterans), expanding to 9/16
when a further study which incorporated emergency ser-
vice personnel were included. Of the remaining studies,
two utilised an urban population, one a kidney transplant
population, and four were population non-specific.
Relationship analysis between biological measures
and sleep was routinely performed however, tri-direc-
tional analysis with PTSD, or PTSD and biological-spe-
cific analyses, was often unexplored or unreported
(Tables S1 and S2). Key outcome measures included
subjective and objective sleep, PTSD symptoms, depres-
sion, HR and variability, blood pressure, inflammatory
and anti-inflammatory status, HPA-axis function and
mRNA gene expression. Sleep assessment methods var-
ied greatly, with 10 different tools employed across the
16 included studies, as visualised in Figure 2. Although
when objective methods were employed, heterogeneity
was greatly reduced with only polysomnography or acti-
graphy utilised.
Articles Identified by database 
search
(n = 513)









Total Articles excluded (n = 91)
No Sleep (n = 34), No PTSD (n = 24), 
No Bio/Physiological (n = 29), Non-







































Figure 1 Summary of literature screening method employed. A total of 513 articles were identified using the search strategy developed. After removal of duplicates, 471
articles were retained for title and abstract screening, following which 38 were retained for full-text eligibility assessment. Sixteen studies were deemed to meet all the
inclusion criteria and were subject to analyses.
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Most studies were designed primarily to examine the
role and relationship of sleep either to psychological
symptomology or biological markers. Study designs varied
but generally can be divided into the following three
categories: epidemiological (Studies 11,13), intervention
(Studies 1,3,4,6,7,8,9,10,15) or night-time specific
(Studies 2,5,12,14). A further study carried out a baseline
group comparison of PTSD vs non-PTSD controls
(Study 16).
Physiological Measures – Assessing
Autonomic Function
Physiological measurements of the cardiovascular or pul-
monary systems were recorded in 11/16 studies (Studies
2,4,5,6,7,9,11,12,13,14,15). Of these, quantification of
blood pressure (BP), or BP regulation was the dominant
measure (6/11). Baroreceptor sensitivity (BRS), a measure
of the ability to regulate BP, was found significantly lower
in a PTSD sub-population (Study 7). This negative rela-
tionship was found to be exacerbated with declines, and
mitigated with gains, in sleep quality, a relationship upheld
with direct examination of blood pressure (Studies 2, 9.11
and 13). However, PTSD status alone was found not to
predict a “non-dipping” designation of nocturnal blood
pressure, an important indicator linking BP and cardiovas-
cular disease (Study 2).88 Although “non-dipping” was
related to poorer sleep quality and was associated with a
more severe PTSD phenotype, with a greater experience of
traumatic events and hyperarousal symptoms.
Used as an estimate of sympathetic and parasympa-
thetic activity, HR and/or heart rate variability (HRV)
measures were examined in 6/11 studies (Studies
4,5,6,9,12,14). Standard deviation of the normal heartbeat
to beat interval (SDNN), a measure indicative of vagal
autonomic influence, decreased following interventions
which concurrently increased sleep quality and decreased
PTSD symptoms (Studies 4,9). However, a direct relation-
ship with insomnia severity index score was not supported
(Study 4). Further measures of HRV included normalised
high frequency (nHF) and low frequency to high-fre-
quency ratio (LF/HF) of respiratory sinus arrhythmia
(RSA), which correlated with total sleep time in trauma
controls but not PTSD (Study 5).89 RSA, indicative of
parasympathetic tone, was investigated in study 15 in
relation to nightmare or distressing dream occurrence in
PTSD.90 Lower sleep period RSA was found predictive of
an increased likelihood of endorsing a nightmare or
distressing dream. Study 15 also noted nightmares or dis-
tressing dreams were associated with an increase in the
number of sleep respiratory events (hypopneas or apneas).
Study 6 examined skin conductance level (SCL) reac-
tivity, a measure indicative of sympathetic activity.
Decreases in SCL reactivity related to decreased night-
mare severity, improvements in self-assessed sleep quality
and a reduction in CAPS assessed PTSD symptom sever-
ity, following exposure, relaxation and re-scripting therapy
(ERRT) for nightmares.
Baseline and night-time HR was evaluated in studies
14 and 12, respectively. An increase in HR was observed
immediately preceding or following nightmare occurrence
(Study 12), albeit baseline comparison between PTSD and
health controls yielded no significance (Study 14).
Interestingly, baseline HR was significantly lower in
trauma controls compared to PTSD (Study 14). HR was
also recorded in study 15 however findings were not
reported.
Biological Measures – Gene Expression
and Biochemical Quantification
Three main biological processes, or systems, were identi-
fied as the focus of the included studies; (1) inflammation,
(2) HPA-axis activity and (3) trophic factor regulation.
With the aim to elucidate the effect sleep has on these
systems in PTSD populations, biochemical and gene
expression analyses were the main techniques employed
and were performed in 7/16 studies.
Inflammation
Biomarkers pertaining to inflammatory status were inves-
tigated in 4/7 studies, in the form of peripheral blood: CRP
(Studies 8,9,16), IL-6 (Studies 8, 16), IL-10 (Study 9),
TNF-α (Study 16), soluble IL-6 receptor (Study 16), IL-
1β (Study 16) and global mRNA gene expression analysis
(Study 3). Improvements in baseline sleep resulted in
differential mRNA expression in 217 coding genes of
which, pro-inflammatory IL-1β, IL-6, IL-8, IL-13, CCL3,
CCL4 and CCL5 genes experienced a significant fold
decrease. A tandem increase in the expression of the
inflammatory regulatory genes TLR1, TLR4, TLR7 and
TLR8, was also observed. Taken together this suggests
that improving sleep is associated with an increase in the
regulation of inflammatory processes, which results in a
global decrease of inflammatory status, a hypothesis
reflected with decreases in plasma IL-6 and CRP mediated
by improved sleep (Studies 8 and 9). However, no
Dovepress Maguire et al
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relationship between Athens insomnia scale assessed sleep
and IL-6, sIL-6R, CRP or TNF-α was noted in Study 16.
In relation to PTSD status and inflammation, reductions to
PTSD symptom severity as assessed by PCL-M followed
improved sleep and were accompanied by a non-signifi-
cant decrease in the expression of the inflammatory reg-
ulatory IL-10 (Study 9). However, no relationship between
PTSD symptom severity and the proinflammatory, CRP,
IL-6, soluble IL-6 receptor, IL-1β and TNF-α cytokines
was substantiated by correlation analysis in Study 16.
HPA-Axis
HPA axis function, considered as a physiological response
to physical and/or psychological stress, formed the basis of
2/7 studies, which measured cortisol, 11-deoxycortisol and
adrenocorticotrophic hormone (ACTH) (Studies 10, 14). A
Maguire et al Dovepress
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Table 2 Summary of Data Extraction from Included Studies
Study 1 2 3 4 5 6 7 8
Reference 117 118 119 120 121 122 123 124







44 61 68 38 38 47 53 66
Males NR 0 66 21 12 8 0 64
Females NR 61 2 17 26 39 53 2
Age 33.3 38.3 22.8 NR 22.8 47.0 41.3 34.9
Study Design Case-controlled Cohort Case-controlled RCT Cohort RCT Cohort Cohort
Sleep
Measures
PSG, ESS, PSQI PSQI PSQI ISI Actigraphy,
Sleep diary
PSQI Actigraphy PSG, PSQI
Intervention CBTI or CBTI +
PAP











CAPS CAPS CAPS PCL-M
Physiological
Measures





BDNF, IGF-1 N/A mRNA N/A N/A N/A N/A IL-6, CRP
Sample
Matrix
Plasma N/A Peripheral Blood N/A N/A N/A N/A Peripheral Blood
Additional
Measures




N/A QIDS, RAND HRQOL
Abbreviations: NR, not reported; N/A, not applicable; RCT, randomized control trial; PSG, polysomnography; ESS, Epworth Sleepiness Scale; PSQI, Pittsburgh Sleep
Quality Index; ISI, Insomnia Severity Index; AIS, Athens Insomnia Scale; CBTI, cognitive behavior therapy for insomnia; PAP, positive airway pressure; RSA, respiratory sinus
arrhythmia; SOC, standard of care; CAN, closed-loop allostatic neurotechnology intervention; PCL, PTSD checklist; CAPS, Clinician Administered PTSD Scale; SCID, Structured
Clinical Interview for DSM-IV; DTS, Davidson Trauma Scale; TSI, Trauma Symptom Inventory; PILL, Pennebaker Inventory of Limbic Languidness; PTCSS, Post Treatment
Clinical Significance Survey; NR, nightmare recall; SCL, skin conductance level; BP, blood pressure; HRV, heart rate variability; BRS, baroreceptor sensitivity; HR, heart rate;
BPM, breaths per minute; REI, Respiratory Event Index; RSA, respiratory sinus arrhythmia; IES-R, Impact of Event Scale-Revised; CTQ, Childhood Trauma Questionnaire;
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comparative group analysis of nocturnal or baseline corti-
sol and ACTH resulted in no significant difference
between PTSD, trauma-exposed (TCs) or health controls
(HCs) (Studies 10.14). Examination of cortisol: ACTH
ratio revealed a significant ratio reduction in PTSD vs
TCs, and borderline significance when compared to HCs,
a finding accentuated between 07:00 and 08:00 am, i.e. the
cortisol awakening response and natural circadian peak.
This appears to suggest decreased responsiveness of the
adrenal cortex to ACTH (Study 14). A finding further
supported by increased 11-deoxycortisol at baseline, with
similar ACTH, observed in PTSD when compared with
controls (Study 10).
Total nocturnal ACTH was positively related to the
number of awakenings, and was an independent, inverse
predictor of slow-wave sleep (Study 14). Congruently, the
9 10 11 12 13 14 15 16
125 126 127 128 129 130 131 132
Military NS Military Military + EMS Kidney Transplant Military Military Japanese
Female
18 66 1855 35 268 45 31 105
17 30 1477 34 138 45 31 0
1 36 378 1 129 0 0 105
40.9 30.0 37.4 43.3 49.9 36.5 41.2 37.4












CAN Metyrapone N/A N/A N/A N/A Canine presence N/A
PCL-M CAPS SCID +
DTS

















N/A N/A Ht, Hb, WBC, PLT,
CRP, Glucose, Urea,
creatinine, proteins,
albumin, Na, K, Ca, P,
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relationship between ACTH and delta power sleep was
negative in PTSD, but not controls (Study 10).
Suggesting increased ACTH in PTSD negatively affects
sleep, a relationship not apparent in control populations.
Administration of a metyrapone challenge to remove
negative feedback to the hypothalamus, by inhibiting cor-
tisol synthesis, resulted in a greater reduction in delta
power sleep, a greater decrease in cortisol and increase
of ACTH levels in PTSD compared to controls (Study 10).
This would suggest an amplified response to the negative
feedback of cortisol at the level of the hypothalamus in
PTSD. Interestingly, improvements to sleep resulted in a
fold increase of glucocorticoid inhibitory FKB506 binding
protein and FK506 binding protein 15 mRNA expression,
potentially relating sleep as an additional element regulat-
ing HPA-axis function (Study 3).
Trophic Factors
Trophic factors, insulin-like growth factor-1 (IGF-1) and
BDNF, implicated in the maintenance of synaptic plasti-
city and learning and memory consolidation, were exam-
ined following a CBT-I intervention to improve sleep
(Study 1). Sleep improvements resulted in a significant
increase in IGF-1 but no significant changes in BDNF
were observed. At baseline, PTSD subgroup analysis
revealed no difference in the concentration of either
trophic factor, and CBT-I treatment reductions in PTSD
symptoms were unrelated to IGF-1 or BDNF changes.
Depression
A wide range of self and clinician-administered psycholo-
gical assessments were reported on, of which depression
was the most common (11/16). Intervention studies which
examined sleep as a function over time reported improve-
ments in sleep were significantly associated with reductions
in depression symptomology (Studies 1,3,8). Congruently,
declines in sleep over time were associated with an increase
in depression ratings. This finding is further supported with
a noted relationship between sleep quality and depression in
kidney transplant recipients (Study 13). Sleep-related
improvements in depression were examined independently
to PTSD status and symptoms.
In summary, five main outcomes were identified; (1)
SDs regulate BP in PTSD, (2) sympathetic dominance in
PTSD is mediated by sleep, (3) sleep regulates global
inflammatory status, (4) protection from glucocorticoid
overexposure in PTSD may be at the expense of sleep
and (5) trophic factor regulation is affected by changes
to sleep in PTSD.
Discussion
To understand the biological interplay between PTSD and
associated SDs, this review evaluated studies which exam-
ined biochemical and/or physiological markers in PTSD
populations, with a specific reference to sleep. Inclusion of
intervention, night-time specific, epidemiological and
baseline studies provided an all-encompassing overview.
Differential sleep period assessments, such as single point
quantifications and time course comparisons, while not
directly comparable, together yield valuable mechanistic
insights into altered biological processes potentially asso-
ciated with sleep in PTSD.
The most commonly reported measure across all studies
was BP or associated BRS. Baroreceptor activation
responds to increased BP by increasing parasympathetic,
and decreasing sympathetic stimulation of the heart and
blood vessels.91,92 Findings of reduced BRS in PTSD popu-
lations were noted to be influenced by sleep quality. Poorer
sleep resulted in further reductions to BRS, which increased
with improvements in sleep, suggesting sympathetic dom-
inance in PTSD can be somewhat reduced by alterations to
sleep, a finding mirrored by HRV and skin conductance
measures. Furthermore, the note that attenuation of sleep
RSA was predictive of nightmare/distressing dream occur-
rence demonstrates this phenomenon is also related to
nightmares in PTSD. This is notable considering that hyper-
tension and cardiovascular disease (CVD) rates are higher
in PTSD populations, suggesting in this population both
sleep quality and nightmares represent targetable and mod-
ifiable CVD drivers which with improvements, could
reduce CVD development in this vulnerable population.83
Nocturnal BP regulation is emerging as a significant
predictor of cardiovascular events in hypertension patients,
with non-dipping (defined as less than 10% decrease in
nocturnal BP vs daytime BP) associated with increased
mortality.93 Non-dipping nocturnal BP was associated with
poorer quality sleep (Study 2). However, PTSD was not
found to be a predictor of dipping status, opposing the
previous observation of reduced BP regulatory ability and
sympathetic dominance in PTSD. Nonetheless, non-dip-
ping was associated with a more severe PTSD phenotype
which fits with the role of cortisol in BP dipping. Reduced
variation in diurnal cortisol is associated with non-dipping
designation.94 Thus, a more severe PTSD phenotype
which results in a protective inhibition of glucocorticoid
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response may represent a mechanism capable of account-
ing for this observation, as discussed further below.93
Findings from this review indicate that a reduced
responsiveness of the adrenal cortex to ACTH stimulation
may exist as a functionally protective mechanism in
PTSD. This results in a reduced cortisol:ACTH ratio,
particularly evident during the cortisol awakening
response, and a greater responsiveness of the hypothala-
mus to cortisol negative feedback removal, as demon-
strated via a cortisol inhibiting metyrapone challenge.
The need to develop such a protective mechanism is
unsurprising considering alterations to circadian oscilla-
tions of glucocorticoids (cortisol) and chronic exposure
have a detrimental effect on synaptic plasticity, learning
and memory.95 However, this may be at the expense of
sleep quality in PTSD, as ACTH was positively related to
the number of night-time awakenings, was an inverse
predictor of restorative slow-wave sleep, and had a nega-
tive relationship with delta power sleep in PTSD.
Improvements to sleep resulted in alterations to glucocor-
ticoid regulatory mRNA expression, further intertwining
sleep and HPA-axis regulation in PTSD.
Specific investigations of this mechanism are warranted
to establish directionality. Are detrimental effects to sleep
resultant from a mechanism aiming to prevent pathologic
exposure to glucocorticoids in PTSD? Or, does poor sleep
quality result in an inappropriate activation of this mechan-
ism, pre-disposing an individual to PTSD development due
to a blunted glucocorticoid responsiveness to stress? Most
likely, we hypothesise a combination of the two is likely to be
true, representing alternative activation arms of a common
mechanism. If validated, this represents a promising research
avenue for the design and development of new, specific
pharmaceuticals for PTSD treatment protocols. Moreover,
reported poor sleep quality could be used to identify PTSD
“at risk” individuals within “at risk” populations (such as
military and first responders), and therapies shown to
improve sleep quality, such as CBT-I for insomnia or night-
mare re-scripting therapy, could be used as prophylactic
treatments potentially capable of reducing PTSD
susceptibility.96
Of further intrigue is the work in mouse models of
PTSD, whereby enforced sleep deprivation following trau-
matic exposure has been found to reduce stress behaviours
associated with recall exposure.97 An effect that was depen-
dant on HPA-axis activity.97 Although such mouse models
of PTSD are translationally limited, this serves as an
additional point reinforcing the importance of the HPA-
axis and sleep in PTSD susceptibility, progression and
treatment.
An increased inflammatory status, associated with
increased mortality risk, has been independently asso-
ciated with SDs, PTSD and other psychiatric conditions
such as depression.49,56,84,85,98,99 Results from this review
indicate improvements to sleep result in both a decrease in
pro-inflammatory cytokines and mRNA expression, and an
increase in inflammatory regulatory mRNA. This suggests
disturbed sleep as a driver of systemic inflammation in
PTSD populations, capable of contributing to comorbid
conditions which are progressed by dysregulated inflam-
matory processes, such as type 2 diabetes and CVD, to
which this population are vulnerable.51–58 However, more
research is required to fully establish the role of inflam-
mation and provide a more complete picture of total
inflammatory status in PTSD, and the role played by
sleep. This review has highlighted that conflictions remain
in the literature between studies examining mRNA expres-
sion and those which examine functional proteins. Perhaps
future studies should aim to examine the role of post-
translational modifications. Our hypothesised protective
inhibition of the HPA-axis, linked to sleep, is particularly
interesting when considered with inflammatory findings.
HPA-axis dysfunction has been linked to dysregulated and
inappropriate inflammatory responses, suggesting these
processes are highly interrelated in PTSD, potentially cau-
sative of one another and possibly linked through sleep.100
To confirm any such relationship between sleep,
inflammation and PTSD, further research should consider
the following limitations of studies included in this review.
Foremost, inflammatory expression changes were not
directly linked to PTSD symptom assessments, therefore
they cannot be assumed to directly relate to PTSD symp-
tom changes. Secondly, it may be necessary to perform tri-
directional analyses which consider depression symptom
changes. Of the included studies which incorporated a
measure of depression, improvements to sleep resulted in
reductions to depression symptoms. As depression is an
inflammatory disease, it is unclear if inflammation changes
are resultant from sleep changes, reductions in depression,
or reductions in PTSD symptom severity in this complex
population.101–103
Examination of the trophic factors IGF-1 and BDNF
noted increases in their expression following improve-
ments to sleep quality, using standard of care sleep thera-
pies. Shown to be decreased in depression, and chronic
Dovepress Maguire et al
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stress, IGF-1 and BDNF are key regulators which modu-
late synaptic plasticity, learning, memory and contextual
fear response.104,105 This finding adds further weight to the
modifiable, central and pathological role of sleep distur-
bances in PTSD.
Perhaps a surprising observation is the lack of investiga-
tion of melatonin and its associated metabolites, considering
its central role in sleep promotion.106 Only a single study
incorporated a melatonin measurement, noting no signifi-
cant differences in overall melatonin secretion or time of
melatonin secretion onset, between PTSD and comparative
populations. However, differences in urine sulphated-mela-
tonin have been observed in PTSD populations when com-
pared to normal controls.107 In future studies, it would be of
interest to examine melatonin metabolites in PTSD popula-
tions following changes to sleep, considering their antiox-
idant properties and the advantages this may present in
PTSD pathobiology.50,75,108
Significant methodological limitations identified as part
of this review are the range of sleep and PTSD assessment
methods currently employed in the field, their reliability
and most importantly their cross comparability. When
comparing biomarkers, having a clear definition of the
test condition is key, particularly if studies are to be
cross-compared to derive any pathobiological mechan-
isms. Some of this disparity in PTSD assessment was
due to the introduction of DSM-5 in 2013.109 However, a
wide range of assessment methods remain in use, which
serve to limit the comparability and generalizability of
biological results across studies. Therefore, this review
recommends that a universal PTSD symptom assessment
method should be adopted for biological investigations.
This problem of method heterogeneity extends to sleep.
Although actigraphy provides a useful objective measure-
ment of sleep in the free-living environment, a key limita-
tion is the use of different devices in different studies, and
unclear reporting of sleep parameter calculation
protocols.15,21,23 Actigraphy devices record movements
which are translated into sleep parameters using scoring
algorithms. To improve the comparability and
Table 3 Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) Assessment of Evidence Quality. Final




Risk of Inconsistency Indirectness Imprecision Publication Bias Overall
Certainty
of Evidence
SDs regulate BP in PTSD (assessed with: BP, BRS)
5 studies Not serious Not serious Serious Not serious All plausible residual confounding would reduce
the demonstrated effect, dose response gradient
⨁⨁⨁◯
MODERATE
Sympathetic dominance in PTSD is mediated by sleep (assessed with: HR, nHF, nHF/LF, RSA, SC)
7 studies Not serious Not serious Not serious Not serious Dose response gradient ⨁⨁⨁◯
MODERATE
Sleep regulates global inflammatory status (assessed with: Peripheral blood cytokines, mRNA expression)




Protection from glucocorticoid over exposure in PTSD is at the expense of sleep (assessed with: Cortisol, 11-Deoxycortisol, ACTH)




Trophic factor regulation improved with improved sleep (assessed with: IGF-1, BDNF)
1 study Serious Not serious Not serious Not serious Strong association, all plausible residual
confounding would reduce the demonstrated
effect, dose response gradient
⨁⨁⨁⨁
HIGH
Abbreviations: SDs, sleep disturbances; PTSD, post-traumatic stress disorder; BP, blood pressure; BRS, baroreceptor sensitivity; HR, heart rate; HRV, heart rate variability;
nHF, normalized high frequency; LF, low frequency; RSA, respiratory sinus arrhythmia; SC, skin conductance; ACTH, adrenocorticotrophic hormone; IGF-1, insulin like
growth factor 1; BDNF, brain derived neurotrophic factor.
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reproducibility between studies, it would be beneficial for
future research to report accelerometer specifications,
sleep parameter calculation algorithms and raw movement
data.19 It was surprising that none of the studies which
employed actigraphy supported this with a valid subjective
sleep assessment method such as the ISI. Incorporation of
such a measurement would allow for greater comparability
with previous studies, and may prove more robust than
objective actigraphy alone.17,18,110 Therefore, this review
recommends future research should report raw acceler-
ometer movement data, in actigraphy-based studies,
where possible. This should also be accompanied by a
validated self-report sleep measure.
As noted previously, recent literature has identified dif-
ferences between the rates of insomnia endorsement and
nightmare occurrence in PTSD.10 Considering this, it is
important to note a large proportion of the included studies
were not able to separate the two, referring instead to a
combined “sleep quality” measure. Therefore, in the case of
PTSD, and perhaps other mental disorders, employing a
combination of sleep quantification methods, so that insom-
nia and nightmares can be clearly differentiated, may allow
any differential effects they have on biological processes to
be identified. Further limitations include the lack of tri-direc-
tional analysis between PTSD symptom measures, sleep and
biological markers and non-universal previous treatment
continuation protocols used by intervention studies.
Less than a third of participants included in this review
were female, despite a two-fold greater susceptibility of
females to the development of PTSD.111 This is most
likely attributable to the dominance of military populations
within the reviewed studies. Despite this disparity in sex,
only five studies consisted of a single-sex population, with
the remaining studies incorporating a very small number
of female participants. This is not preferable when exam-
ining biochemical or physiological markers, which have
normal variations due to sex, and should be addressed in
future research.112–115
Limitations
Findings of this review are limited by the small number of
studies which met all inclusion criteria and an assumed com-
parability between the different PTSD, subjective sleep, and
objective sleep assessment methods used across studies.
Conclusions and Future Directions
The aim of this review was to establish if biochemical and/
or physiological markers are related to SDs, severity of the
disturbances and their resolution in PTSD. In this regard,
SDs were found to directly affect physiological markers
relating to autonomic function, and biochemical markers
relating to HPA-axis activity, systemic inflammatory pro-
cesses and trophic factor regulation thus, not only do SDs
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
PERCENTAGE OF STUDIES
Sleep Assessment Methods
Pittsburgh Sleep Quality Index Polysomnography Sleep diary
Actigraphy Trauma related nightmare survey Symptom checklist 90
Insomnia Severity Inventory Epworth Sleepiness Scale Athens Insomnia Scale
Nightmare recall
Figure 2 Graphic showing the different sleep assessment methods employed across the included studies, as a percentage of the total number methods. Pittsburgh Sleep
Quality Index (21.7%), Polysomnography (21.7%), Sleep diary (17.4%), Actigraphy (13%), Trauma-related nightmare survey (4.3%), Symptom checklist 90 (4.3%), Insomnia
Severity Inventory (4.3%), Epworth Sleepiness Scale (4.3%), Athens Insomnia Scale (4.3%), dichotomous nightmare recall (4.3%).
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reduce quality of life, but they also contribute to overall
morbidity and mortality associated with PTSD.
Findings pertaining to changes in sleep over time
established sleep as a central driver playing a role in, and
potentially capable of modifying, many pathological path-
ways. Improving sleep was shown to decrease sympathetic
dominance, increase trophic factor concentrations and
reduce pro-inflammatory processes. Improving sleep qual-
ity, therefore, has the potential to reduce all-cause lifetime
mortality associated with CVD, diabetes and other meta-
bolic conditions in PTSD, and as such should be of central
focus when developing treatment regimes. Resolving SDs
will not only reduce the overall severity of PTSD symp-
toms but also has the potential to reduce hospital admis-
sion time, total lifetime healthcare costs and improve the
overall quality of life for those with PTSD.
Looking into the future, mechanistic insights of this review
highlight the importance of carrying out further research into
the ability of prophylactic sleep therapies, such as CBT-I, to
reduce PTSD risk in populations of high trauma exposure, such
as the military and first responders. Such research should be
conducted, and findings used in conjunction with those of this
review, to inform future policy and occupational health prac-
tices in these populations. If this is carried out and appropriate
practices implemented, not only could it reduce the risk of
developing PTSD, but it may also bring additional economic
benefits to employers through reduced sickness-related time
off work, and compensation payments associatedwith occupa-
tional-related PTSD.116 However, to allow cross-comparabil-
ity and expand the generalizability of findings, future research
must address and adhere to the methodological recommenda-
tions laid out in this review.
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